Improving DNA vaccine performance through vector design

Current Gene Therapy

Volumn 14, Issue 3, 2014, Pages 170-189

  Williams, James A ^a  

^a NATURE TECHNOLOGY CORPORATION   (United States)

Author keywords

Antibiotic free; DNA vaccination; Fermentation; Non viral; Plasmid; Vector

Indexed keywords

BACTERIAL RNA; DNA VACCINE; DOUBLE STRANDED RNA; GLYCOSYLPHOSPHATIDYLINOSITOL; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NEUTRALIZING ANTIBODY; RIBOSOME RNA; TATA BINDING PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR; TRANSFER RNA; ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; BIOINFORMATICS; DNA IMMUNIZATION; ELECTROPORATION; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; ISOLATION AND PURIFICATION; NONHUMAN; PLASMID; QUALITY CONTROL; TRANSCRIPTION REGULATION; VIRAL GENE THERAPY; ANIMAL; CHEMISTRY; GENE VECTOR; GENETICS; METABOLISM; TRANSGENE; VACCINATION;

ANIMALIA;

ANIMALS; ANTIGENS; ELECTROPORATION; GENETIC VECTORS; HUMANS; PLASMIDS; TRANSGENES; VACCINATION; VACCINES, DNA;

EID: 84906914729     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652321403140819122538     Document Type: Review

References (236)

1. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239(1):62-84.
2. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9(10):776-88.
3. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7(2):175-91.
4. Cavlar T, Ablasser A, Hornung V. Induction of type I IFNs by intracellular DNA-sensing pathways. Immunol Cell Biol 2012; 90(5):474-82.
5. Liu MA. Immunologic basis of vaccine vectors. Immunity 2010; 33(4):504-15.
6. Coban C, Kobiyama K, Aoshi T, et al. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 2011; 11(6):479-84.
7. Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin 2008; 4(6):453-6.
8. Civril F, Deimling T, de Oliveira Mann CC, et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 2013; 498(7454):332-7.
9. Coban C, Kobiyama K, Jounai N, Tozuka M, Ishii KJ. DNA vaccines: A simple DNA sensing matter? Hum Vaccin Immunother 2013; 9(10):2216-21.
10. Pavlenko M, Leder C, Moreno S, Levitsky V, Pisa P. Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9and MyD88-deficient mice. Vaccine 2007; 25(34):6341-7.
11. Rottembourg D, Filippi CM, Bresson D, et al. Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection. J Immunol 2010; 184(12):7100-7.
12. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26(5):549-51.
13. Warren SE, Armstrong A, Hamilton MK, et al. Cutting edge: Cytosolic bacterial DNA activates the inflammasome via Aim2. J Immunol 2010; 185(2):818-21.
14. Premenko-Lanier M, Rota PA, Rhodes GH, Bellini WJ, McChesney MB. Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in James A. Williams the presence of neutralizing antibody. J Infect Dis 2004; 189(11):2064-71.
15. Walther W, Schmeer M, Kobelt D, et al. A Seven-Year Storage Report of Good Manufacturing Practice-Grade Naked Plasmid DNA: Stability, Topology, and In vitro/In vivo Functional Analysis. Hum Gene Ther Clin Dev 2013; 24(4):147-53.
16. Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, Lu S. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008; 26(29-30):3626-33.
17. Khurana S, Wu J, Dimitrova M, et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-intervaldependent manner in adults. J Infect Dis 2013; 208(3):413-7.
18. Ledgerwood JE, Zephir K, Hu Z, et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013; 208(3):418-22.
19. Wei CJ, Boyington JC, McTamney PM, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329(5995):1060-4.
20. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11(12):916-24.
21. Lingwood D, McTamney PM, Yassine HM, et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 2012; 489(7417):566-70.
22. Chiarella P, Fazio VM, Signori E. Application of electroporation in DNA vaccination protocols. Curr Gene Ther 2010; 10(4):281-6.
23. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011; 23(3):421-9.
24. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants. Front Immunol 2013; 4:354.
25. Ault A, Zajac AM, Kong WP, et al. Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine 2012; 30(26):3965-74.
26. Gorres JP, Lager KM, Kong WP, et al. DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs. Clin Vaccine Immunol 2011; 18(11):1987-95.
27. Ledgerwood JE, Hu Z, Gordon IJ, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19(11):1792-7.
28. Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A. Vaxfectin: a versatile adjuvant for plasmid DNAand protein-based vaccines. Expert Opin Drug Deliv 2010; 7(12):1433-46.
29. Wang Y, Guo Y, Wang X, Huang J, Shang J, Sun S. Human serum amyloid P functions as a negative regulator of the innate and adaptive immune responses to DNA vaccines. J Immunol 2011; 186(5):2860-70.
30. Wang Y, Guo Y, Wang X, Huang J, Shang J, Sun S. Serum amyloid P component facilitates DNA clearance and inhibits plasmid transfection: implications for human DNA vaccine. Gene Ther 2012; 19(1):70-7.
31. Rosazza C, Escoffre JM, Zumbusch A, Rols MP. The actin cytoskeleton has an active role in the electrotransfer of plasmid DNA in mammalian cells. Mol Ther. 2011;19(5):913-21.
32. Lam AP, Dean DA. Progress and prospects: nuclear import of nonviral vectors. Gene Ther 2010; 17(4):439-47.
33. Li C, Goudy K, Hirsch M, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A 2009; 106(26):10770-4.
34. Hartikka J, Sawdey M, Cornefert-Jensen F, et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996; 7(10):1205-17.
35. Williams JA, Luke J, Johnson L, Hodgson C. pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids. Vaccine 2006; 24(21):4671-6.
36. Lemp NA, Hiraoka K, Kasahara N, Logg CR. Cryptic transcripts from a ubiquitous plasmid origin of replication confound tests for cis-regulatory function. Nucleic Acids Res 2012; 40(15):7280-90.
37. Nejepinska J, Malik R, Moravec M, Svoboda P. Deep sequencing reveals complex spurious transcription from transiently transfected plasmids. PLoS One 2012; 7(8):e43283.
38. Nejepinska J, Malik R, Wagner S, Svoboda P. Reporters transiently transfected into mammalian cells are highly sensitive to translational repression induced by dsRNA expression. PLoS One 2014; 9(1):e87517.
39. Carnes AE, Luke JM, Vincent JM, et al. Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields. J Gene Med 2010; 12(10):818-31.
40. Williams JA, Carnes AE, Hodgson CP. Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv 2009; 27(4):353-70.
41. Mairhofer J, Grabherr R. Rational vector design for efficient nonviral gene delivery: challenges facing the use of plasmid DNA. Mol Biotechnol 2008; 39(2):97-104.
42. Gill DR, Pringle IA, Hyde SC. Progress and prospects: the design and production of plasmid vectors. Gene Ther 2009; 16(2):165-71.
43. Oliveira PH, Prather KJ, Prazeres DM, Monteiro GA. Structural instability of plasmid biopharmaceuticals: challenges and implications. Trends Biotechnol 2009; 27(9):503-11.
44. Oliveira PH, Prather KL, Prazeres DM, Monteiro GA. Mutation detection in plasmid-based biopharmaceuticals. Biotechnol J 2011; 6(4):378-91.
45. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012; 162(2-3):171-82.
46. Williams JA. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines 2013; 1:225-49.
47. FDA. Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications. USA Food and Drug Administration; 2007.
48. EMA. Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products.: European Medicines Agency; 2001.
49. Presence of the antibiotic resistance marker gene nptII in GM plants and food and feed uses. European Medicines Agency; 2007.
50. Luke JM, Vincent JM, Du SX, et al. Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Ther 2011; 18(4):334-43.
51. Schirmbeck R, Riedl P, Fissolo N, Lemonnier FA, Bertoletti A, Reimann J. Translation from cryptic reading frames of DNA vaccines generates an extended repertoire of immunogenic, MHC class I-restricted epitopes. J Immunol 2005; 174(8):4647-56.
52. Liu HX, Zhang M, Krainer AR. Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev 1998; 12(13):1998-2012.
53. Fairbrother WG, Yeh RF, Sharp PA, Burge CB. Predictive identification of exonic splicing enhancers in human genes. Science 2002; 297(5583):1007-13.
54. Wang Y, Ma M, Xiao X, Wang Z. Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules. Nat Struct Mol Biol 2012; 19(10):1044-52.
55. Barouch DH, Yang ZY, Kong WP, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 2005; 79(14):8828-34.
56. Takahashi Y, Nishikawa M, Takiguchi N, Suehara T, Takakura Y. Saturation of transgene protein synthesis from mRNA in cells producing a large number of transgene mRNA. Biotechnol Bioeng 2011; doi: 10.1002/bit.23179. [Epub ahead of print].
57. Cooke JR, McKie EA, Ward JM, Keshavarz-Moore E. Impact of intrinsic DNA structure on processing of plasmids for gene therapy and DNA vaccines. J Biotechnol 2004; 114(3):239-54.
58. Luke JM, Carnes AE, Hodgson CP, Williams JA. Vector inserttargeted integrative antisense expression system for plasmid stabilization. Mol Biotechnol 2011; 47(1):43-9.
59. Kalams SA, Parker SD, Elizaga M, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208(5):818-29.
60. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012; 11(2):189-209.
61. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012; 12(7):479-91.
62. Kobiyama K, Jounai N, Aoshi T, et al. Innate immune signaling by, and genetic adjuvants for DNA vaccination. Vaccines 2013; 1:278-92.
63. Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010; 10(4):312-7.
64. Fioretti D, Iurescia S, Rinaldi M. Recent advances in design of immunogenic and effective naked DNA vaccines against cancer. Recent Pat Anticancer Drug Discov 2014; 9(1):66-82.
65. Marchini C, Kalogris C, Garulli C, et al. Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. Front Oncol 2013; 3:122.
66. Evel-Kabler K, Chen SY. Inhibition of antigen-presentation attenuators to augment vaccines. Curr Opin Mol Ther 2006; 8(1):24-30.
67. Song XT, Evel-Kabler K, Rollins L, et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 2006; 3(1):e11.
68. Huang B, Mao CP, Peng S, Hung CF, Wu TC. RNA interferencemediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther 2008; 19(8):763-73.
69. Senzer N, Barve M, Kuhn J, et al. Phase I trial of bishRNAi(furin)/GMCSF DNA/autologous tumor cell vaccine (FANG) in advanced cancer. Mol Ther 2012; 20(3):679-86.
70. Wheatley AK, Kramski M, Alexander MR, Toe JG, Center RJ, Purcell DF. Co-expression of miRNA targeting the expression of PERK, but not PKR, enhances cellular immunity from an HIV-1 Env DNA vaccine. PLoS One 2011; 6(3):e18225.
71. Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol 2013;13(8):551-65.
72. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001; 98(16):9237-42.
73. Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M. The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 2011; 128(2):473-81.
74. Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol 2005; 78(3):647-55.
75. Li D, Liu Y, Zhang Y, et al. Adjuvant effects of plasmid-generated hairpin RNA molecules on DNA vaccination. Vaccine 2007; 25(39-40):6992-7000.
76. Luke JM, Simon GG, Soderholm J, et al. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol 2011; 85(3):1370-83.
77. Wu J, Ma H, Qu Q, et al. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice. Vaccine 2011; 29(44):7624-30.
78. Martinez-Gil L, Goff PH, Hai R, Garcia-Sastre A, Shaw ML, Palese P. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol 2013; 87(3):1290-300.
79. Vabret N, Blander JM. Sensing Microbial RNA in the Cytosol. Front Immunol 2013; 4:468.
80. Arsenault RJ, Kogut MH, He H. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands. Cell Signal 2013; 25(11):2246-54.
81. Reyes-Lamothe R, Tran T, Meas D, et al. High-copy bacterial plasmids diffuse in the nucleoid-free space, replicate stochastically and are randomly partitioned at cell division. Nucleic Acids Res 2013; 42(2):1042-51.
82. Chen J, Jin M, Qiu ZG, et al. A survey of drug resistance bla genes originating from synthetic plasmid vectors in six Chinese rivers. Environ Sci Technol 2012; 46(24):13448-54.
83. Gene transfer medical products for human use. European Pharmacopeia 7.0; 2011. p. 648.
84. Vandermeulen G, Marie C, Scherman D, Preat V. New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol Ther 2011; 19(11):1942-9.
85. Oliveira PH, Mairhofer J. Marker-free plasmids for biotechnological applications implications and perspectives. Trends Biotechnol 2013; 31(9):539-47.
86. Luke J, Carnes AE, Hodgson CP, Williams JA. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 2009; 27(46):6454-9.
87. Soubrier F, Cameron B, Manse B, et al. pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Ther 1999; 6(8):1482-8.
88. Marie C, Vandermeulen G, Quiviger M, Richard M, Preat V, Scherman D. pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. J Gene Med 2010; 12(4):323-32.
89. Mairhofer J, Pfaffenzeller I, Merz D, Grabherr R. A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy. Biotechnol J 2008; 3(1):83-9.
90. Cranenburgh RM, Plasmid Maintenance. USA patent 7611883. 2009.
91. Nelson J, Rodriguez S, Finlayson N, Williams J, Carnes A. Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process. Hum Vaccin Immunother 2013; 9(10).
92. Mairhofer J, Cserjan-Puschmann M, Striedner G, Nobauer K, Razzazi-Fazeli E, Grabherr R. Marker-free plasmids for gene therapeutic applications-lack of antibiotic resistance gene substantially improves the manufacturing process. J Biotechnol 2010; 146(3):130-7.
93. Luke JM, Carnes AE, Williams JA. Development of antibiotic-free selection system for safer DNA vaccination. Methods Mol Biol 2014; 1143:91-111.
94. Artelt P, Grannemann R, Stocking C, Friel J, Bartsch J, Hauser H. The prokaryotic neomycin-resistance-encoding gene acts as a transcriptional silencer in eukaryotic cells. Gene 1991; 99(2):249-54.
95. Ribeiro S, Mairhofer J, Madeira C, et al. Plasmid DNA size does affect nonviral gene delivery efficiency in stem cells. Cell Reprogram 2012; 14(2):130-7.
96. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS. Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem 2000; 275(3):1625-9.
97. Kreiss P, Cameron B, Rangara R, et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res 1999; 27(19):3792-8.
98. Yin W, Xiang P, Li Q. Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal Biochem 2005; 346(2):289-94.
99. Stenler S, Wiklander OP, Badal-Tejedor M, et al. Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression. Mol Ther Nucleic Acids 2014;2:e140.
100. Lu J, Zhang F, Xu S, Fire AZ, Kay MA. The extragenic spacer length between the 5' and 3' ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors. Mol Ther 2012; 20(11):2111-9.
101. Gracey Maniar LE, Maniar JM, Chen ZY, Lu J, Fire AZ, Kay MA. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol Ther 2013; 21(1):131-8.
102. Padegimas L, Kowalczyk TH, Adams S, et al. Optimization of hCFTR lung expression in mice using DNA nanoparticles. Mol Ther 2012; 20(1):63-72.
103. Hagedorn C, Wong SP, Harbottle R, Lipps HJ. Scaffold/matrix attached region-based nonviral episomal vectors. Hum Gene Ther 2011; 22(8):915-23.
104. Lee NC, Kononenko AV, Lee HS, et al. Protecting a transgene expression from the HAC-based vector by different chromatin insulators. Cell Mol Life Sci 2013; 70(19):3723-37.
105. Hagedorn C, Antoniou MN, Lipps HJ. Genomic cis-acting Sequences Improve Expression and Establishment of a Nonviral Vector. Mol Ther Nucleic Acids 2013; 2:e118.
106. Puttini S, van Zwieten RW, Saugy D, et al. MAR-mediated integration of plasmid vectors for in vivo gene transfer and regulation. BMC Mol Biol 2013; 14:26.
107. Hovav AH, Panas MW, Rahman S, et al. Duration of antigen expression in vivo following DNA immunization modifies the magnitude, contraction, and secondary responses of CD8+ T lymphocytes. J Immunol 2007; 179(10):6725-33.
108. Finn JD, Bassett J, Millar JB, et al. Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J Virol 2009; 83(23):12027-36.
109. Bachmann MF, Beerli RR, Agnellini P, Wolint P, Schwarz K, Oxenius A. Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol 2006; 36(4):842-54.
110. Dietz WM, Skinner NE, Hamilton SE, et al. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther 2013; 21(8):1526-35.
111. Wang Q, Jiang W, Chen Y, et al. In vivo Electroporation of Minicircle DNA as a Novel Method of Vaccine Delivery to Enhance HIV-1-Specific Immune Responses. J Virol 2013; 88(4):1924-34.
112. Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors. Nat Biotechnol 2010; 28(12):1287-9.
113. Williams JA, DNA plasmids with improved expression. USA patent PCT/US 13/00067. 2013.
114. Lu J, Zhang F, Kay MA. A Mini-intronic Plasmid (MIP): A Novel Robust Transgene Expression Vector In vivo and In vitro. Mol Ther 2013; 21(5):954-63.
115. Williams JA, Replicative minicircle vectors with improved expression. USA patent PCT/US 13/00067. 2013.
116. Williams JA, Replicative minicircle vectors with improved expression. USA patent PCT/US2013/000259. 2013.
117. Koff WC, Burton DR, Johnson PR, et al. Accelerating nextgeneration vaccine development for global disease prevention. Science 2013; 340(6136):1232910.
118. Smith LR, Wloch MK, Chaplin JA, Gerber M, Rolland AP. Clinical development of a Cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial. Vaccines 2013; 1:398-414.
119. Dormitzer PR, Ulmer JB, Rappuoli R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol 2008; 26(12):659-67.
120. Moise L, Cousens L, Fueyo J, De Groot AS. Harnessing the power of genomics and immunoinformatics to produce improved vaccines. Expert Opin Drug Discov 2011; 6(1):9-15.
121. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9(4):1284-90.
122. Dupuy LC, Schmaljohn CS. DNA vaccines for biodefense. Expert Rev Vaccines 2009; 8(12):1739-54.
123. Bragstad K, Vinner L, Hansen MS, Nielsen J, Fomsgaard A. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection. Vaccine 2013; 31(18):2281-8.
124. Dupuy LC, Richards MJ, Ellefsen B, et al. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol 2011; 18(5):707-16.
125. Hooper JW, Thompson E, Wilhelmsen C, et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 2004; 78(9):4433-43.
126. Albrecht MT, Livingston BD, Pesce JT, Bell MG, Hannaman D, Keane-Myers AM. Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague. Vaccine 2012; 30(32):4872-83.
127. Stab V, Nitsche S, Niezold T, et al. Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus. PLoS One 2013; 8(8):e72217.
128. Toapanta FR, Craigo JK, Montelaro RC, Ross TM. Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope. Curr HIV Res 2007; 5(2):199-209.
129. Sedegah M, Charoenvit Y, Minh L, et al. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 2004; 11(5):448-56.
130. Rao S, Kong WP, Wei CJ, et al. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 2008; 3(6):e2432.
131. Obeng-Adjei N, Hutnick NA, Yan J, et al. DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Ther 2013; 20(12):652-62.
132. Mir FA, Kaufmann SH, Eddine AN. A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire. Clin Vaccine Immunol 2009; 16(10):1467-75.
133. Liang R, Babiuk LA, van Drunen Littel-van den Hurk S. Compatibility of plasmids encoding bovine viral diarrhea virus type 1 and type 2 E2 in a single DNA vaccine formulation. Vaccine 2007; 25(32):5994-6006.
134. Jalah R, Rosati M, Ganneru B, et al. The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem 2013; 288(9):6763-76.
135. Laddy DJ, Yan J, Khan AS, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009; 83(9):4624-30.
136. Dupuy LC, Locher CP, Paidhungat M, et al. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine 2009; 27(31):4152-60.
137. Moise L, Terry F, Ardito M, et al. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Hum Vaccin Immunother 2013; 9(7):1598-607.
138. Moise L, Tassone R, Latimer H, et al. Immunization with crossconserved H1N1 influenza CD4(+) T-cell epitopes lowers viral burden in HLA DR3 transgenic mice. Hum Vaccin Immunother 2013; 9(10):2060-8.
139. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333(6044):850-6.
140. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 2012; 86(11):6179-88.
141. Yamazaki T, Nagashima M, Ninomiya D, et al. Passive immuneprophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids. Jpn J Infect Dis 2011; 64(1):40-9.
142. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492(7427):118-22.
143. Pace CS, Song R, Ochsenbauer C, et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A 2013; 110(33):13540-5.
144. Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother 2013; 9(10):2253-62.
145. Li J, Valentin A, Kulkarni V, et al. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013; 31(36):3747-55.
146. Pissani F, Malherbe DC, Schuman JT, et al. Improvement of antibody responses by HIV envelope DNA and protein coimmunization. Vaccine 2014; 32(4):507-13.
147. Jin H, Kang Y, Zheng G, et al. Induction of active immune suppression by co-immunization with DNAand protein-based vaccines. Virology 2005; 337(1):183-91.
148. Geng S, Yu Y, Kang Y, et al. Efficient induction of CD25iTreg by co-immunization requires strongly antigenic epitopes for T cells. BMC Immunol 2011; 12:27.
149. Li J, Geng S, Liu X, et al. DNA and protein co-administration induces tolerogenic dendritic cells through DC-SIGN mediated negative signals. Hum Vaccin Immunother 2013; 9(10):2237-45.
150. Jin H, Xiao C, Geng S, et al. Protein/DNA vaccine-induced antigen-specific Treg confer protection against asthma. Eur J Immunol 2008; 38(9):2451-63.
151. Jin J, Ding Z, Meng F, et al. An immunotherapeutic treatment against flea allergy dermatitis in cats by co-immunization of DNA and protein vaccines. Vaccine 2010; 28(8):1997-2004.
152. Wang G, Pan L, Zhang Y. Approaches to improved targeting of DNA vaccines. Hum Vaccin 2011; 7(12):1271-81.
153. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 1999; 67(9):4780-6.
154. Wallace A, West K, Rothman AL, Ennis FA, Lu S, Wang S. Posttranslational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). Hum Vaccin Immunother 2013; 9(10):2095-102.
155. Martinez-Lopez A, Garcia-Valtanen P, Ortega-Villaizan Mdel M, et al. Increasing versatility of the DNA vaccines through modification of the subcellular location of plasmid-encoded antigen expression in the in vivo transfected cells. PLoS One 2013; 8(10):e77426.
156. Wang S, Farfan-Arribas DJ, Shen S, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006; 24(21):4531-40.
157. Jalah R, Rosati M, Kulkarni V, et al. Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol 2007; 26(12):827-40.
158. Wang S, Hackett A, Jia N, et al. Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One 2011; 6(12):e28757.
159. Golden JW, Josleyn MD, Hooper JW. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 2008; 26(27-28):3507-15.
160. Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B. DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J Immunol 2013; 191(6):3221-31.
161. Rodriguez F, An LL, Harkins S, et al. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 1998; 72(6):5174-81.
162. Dutton JL, Li B, Woo WP, et al. A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PLoS One 2013; 8(10):e76407.
163. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995; 92(25):11671-5.
164. Marques ET, Jr., Chikhlikar P, de Arruda LB, et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 2003; 278(39):37926-36.
165. Chuang YH, Yang YH, Wu SJ, Chiang BL. Gene therapy for allergic diseases. Curr Gene Ther 2009; 9(3):185-91.
166. Bauer R, Scheiblhofer S, Kern K, et al. Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J Allergy Clin Immunol 2006; 118(1):269-76.
167. Weinberger EE, Isakovic A, Scheiblhofer S, et al. The influence of antigen targeting to sub-cellular compartments on the anti-allergic potential of a DNA vaccine. Vaccine 2013; 31(51):6113-21.
168. Tan LK, Huang CH, Kuo IC, Liew LM, Chua KY. Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production. Vaccine 2006; 24(29-30):5762-71.
169. Scheiblhofer S, Stoecklinger A, Gruber C, et al. Gene gun immunization with clinically relevant allergens aggravates allergen induced pathology and is contraindicated for allergen immunotherapy. Mol Immunol 2007; 44(8):1879-87.
170. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8(2):108-20.
171. Kutzler MA, Robinson TM, Chattergoon MA, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005; 175(1):112-23.
172. Fath S, Bauer AP, Liss M, et al. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One 2011; 6(3):e17596.
173. Mahlab S, Linial M. Speed controls in translating secretory proteins in eukaryotes--an evolutionary perspective. PLoS Comput Biol 2014; 10(1):e1003294.
174. Krinner S, Heitzer AP, Diermeier SD, Obermeier I, Langst G, Wagner R. CpG domains downstream of TSSs promote high levels of gene expression. Nucleic Acids Res 2014; 42(6):3551-64.
175. Bauer AP, Leikam D, Krinner S, et al. The impact of intragenic CpG content on gene expression. Nucleic Acids Res 2010; 38(12):3891-908.
176. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31(13):3406-15.
177. Wang Z, Troilo PJ, Wang X, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004; 11(8):711-21.
178. Kimelman A, Levy A, Sberro H, et al. A vast collection of microbial genes that are toxic to bacteria. Genome Res 2012; 22(4):802-9.
179. Carnes AE, Williams JA. Plasmid DNA manufacturing technology. Recent Pat Biotechnol 2007; 1(2):151-66.
180. Carnes AE, Williams JA, Process for plasmid DNA fermentation. USA patent 7943377. 2011.
181. Carnes AE, Luke JM, Vincent JM, et al. Plasmid DNA fermentation strain and process-specific effects on vector yield, quality, and transgene expression. Biotechnol Bioeng 2011; 108(2):354-63.
182. Williams JA, Luke J, Langtry S, Anderson S, Hodgson CP, Carnes AE. Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes. Biotechnol Bioeng 2009; 103(6):1129-43.
183. Urthaler J, Schuchnigg H, Garidel P, Huber H. Industrial manufacturing of plasmid-DNA products for gene vaccination and therapy. In: Thalhamer J, Weiss R, Scheiblhofer S, editors. Gene Vaccines. 3. New York, USA: SpringerWienNewYork; 2012. p. 311-30.
184. Prather KL, Edmonds MC, Herod JW. Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines. Appl Microbiol Biotechnol 2006; 73(4):815-26.
185. van der Heijden I, Gomez-Eerland R, van den Berg JH, et al. Transposon leads to contamination of clinical pDNA vaccine. Vaccine 2013; 31(32):3274-80.
186. Posfai G, Plunkett G, 3rd, Feher T, et al. Emergent properties of reduced-genome Escherichia coli. Science 2006; 312(5776):1044-6.
187. Csorgo B, Feher T, Timar E, Blattner FR, Posfai G. Low-mutationrate, reduced-genome Escherichia coli: an improved host for faithful maintenance of engineered genetic constructs. Microb Cell Fact 2012; 11:11.
188. Akeno Y, Ying BW, Tsuru S, Yomo T. A reduced genome decreases the host carrying capacity for foreign DNA. Microb Cell Fact 2014; 13(1):49.
189. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 1979; 7(6):1513-23.
190. Sayers JR, Evans D, Thomson JB. Identification and eradication of a denatured DNA isolated during alkaline lysis-based plasmid purification procedures. Anal Biochem 1996; 241(2):186-9.
191. Evans RK, Xu Z, Bohannon KE, Wang B, Bruner MW, Volkin DB. Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies. J Pharm Sci 2000; 89(1):76-87.
192. Cai Y, Rodriguez S, Hebel H. DNA vaccine manufacture: scale and quality. Expert Rev Vaccines 2009; 8(9):1277-91.
193. Hoare M, Levy MS, Bracewell DG, et al. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic. Biotechnol Prog 2005; 21(6):1577-92.
194. Sousa A, Sousa F, Queiroz JA. Advances in chromatographic supports for pharmaceutical-grade plasmid DNA purification. J Sep Sci 2012; 35(22):3046-58.
195. Ghanem A, Healey R, Adly FG. Current trends in separation of plasmid DNA vaccines: a review. Anal Chim Acta 2013; 760:1-15.
196. Escoffre JM, Nikolova B, Mallet L, et al. New insights in the gene electrotransfer process: evidence for the involvement of the plasmid DNA topology. Curr Gene Ther 2012; 12(5):417-22.
197. Leahy P, Carmichael GG, Rossomando EF. Transcription from plasmid expression vectors is increased up to 14-fold when plasmids are transfected as concatemers. Nucleic Acids Res 1997;25(2):449-50.
198. Maucksch C, Bohla A, Hoffmann F, et al. Transgene expression of transfected supercoiled plasmid DNA concatemers in mammalian cells. J Gene Med 2009; 11(5):444-53.
199. Molloy MJ, Hall VS, Bailey SI, Griffin KJ, Faulkner J, Uden M. Effective and robust plasmid topology analysis and the subsequent characterization of the plasmid isoforms thereby observed. Nucleic Acids Res 2004; 32(16):e129.
200. Badger CV, Richardson JD, Dasilva RL, et al. Development and application of a flow cytometric potency assay for DNA vaccines. Vaccine 2011; 29(39):6728-35.
201. Mahajan R, Feher B, Jones B, et al. A TaqMan reverse transcription polymerase chain reaction (RT-PCR) in vitro potency assay for plasmid-based vaccine products. Mol Biotechnol 2008; 40(1):47-57.
202. Hidmark A, von Saint Paul A, Dalpke AH. Cutting edge: TLR13 is a receptor for bacterial RNA. J Immunol 2012; 189(6):2717-21.
203. De La Vega J, Braak BT, Azzoni AR, Monteiro GA, Prazeres DM. Impact of plasmid quality on lipoplex-mediated transfection. J Pharm Sci 2013; 102(11):3932-41.
204. Wooddell CI, Subbotin VM, Sebestyen MG, et al. Muscle damage after delivery of naked plasmid DNA into skeletal muscles is batch dependent. Hum Gene Ther 2011; 22(2):225-35.
205. Bazzani RP, Cai Y, Hebel HL, Hyde SC, Gill DR. The significance of plasmid DNA preparations contaminated with bacterial genomic DNA on inflammatory responses following delivery of lipoplexes to the murine lung. Biomaterials 2011; 32(36):9854-65.
206. Firozi P, Zhang W, Chen L, Quiocho FA, Worley KC, Templeton NS. Identification and removal of colanic acid from plasmid DNA preparations: implications for gene therapy. Gene Ther 2010; 17(12):1484-99.
207. Smith GJ, 3rd, Helf M, Nesbet C, Betita HA, Meek J, Ferre F. Fast and accurate method for quantitating E. coli host-cell DNA contamination in plasmid DNA preparations. Biotechniques 1999; 26(3):518-22, 24, 26.
208. Goncalves GA, Prazeres DM, Monteiro GA, Prather KL. De novo creation of MG1655-derived E. coli strains specifically designed for plasmid DNA production. Appl Microbiol Biotechnol 2013; 97(2):611-20.
209. Phue JN, Lee SJ, Trinh L, Shiloach J. Modified Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5alpha). Biotechnol Bioeng 2008; 101(4):831-6.
210. Goncalves GA, Bower DM, Prazeres DM, Monteiro GA, Prather KL. Rational engineering of Escherichia coli strains for plasmid biopharmaceutical manufacturing. Biotechnol J 2012; 7(2):251-61.
211. Yau SY, Keshavarz-Moore E, Ward J. Host strain influences on supercoiled plasmid DNA production in Escherichia coli: Implications for efficient design of large-scale processes. Biotechnol Bioeng 2008; 101(3):529-44.
212. Blair DG, Sherratt DJ, Clewell DB, Helinski DR. Isolation of supercoiled colicinogenic factor E 1 DNA sensitive to ribonuclease and alkali. Proc Natl Acad Sci U S A 1972; 69(9):2518-22.
213. Carnes AE, Hodgson CP, Williams JA. Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol Appl Biochem 2006; 45(Pt 3):155-66.
214. Parry BR, Surovtsev IV, Cabeen MT, O'Hern CS, Dufresne ER, Jacobs-Wagner C. The Bacterial Cytoplasm Has Glass-like Properties and Is Fluidized by Metabolic Activity. Cell 2013; 156(1-2):183-94.
215. Schvartzman JB, Martinez-Robles ML, Hernandez P, Krimer DB. Plasmid DNA replication and topology as visualized by twodimensional agarose gel electrophoresis. Plasmid 2010; 63(1):1-10.
216. Zechiedrich EL, Khodursky AB, Bachellier S, et al. Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli. J Biol Chem 2000; 275(11):8103-13.
217. Deibler RW, Rahmati S, Zechiedrich EL. Topoisomerase IV, alone, unknots DNA in E. coli. Genes Dev 2001; 15(6):748-61.
218. Goldstein E, Drlica K. Regulation of bacterial DNA supercoiling: plasmid linking numbers vary with growth temperature. Proc Natl Acad Sci U S A 1984; 81(13):4046-50.
219. Balke VL, Gralla JD. Changes in the linking number of supercoiled DNA accompany growth transitions in Escherichia coli. J Bacteriol 1987; 169(10):4499-506.
220. Cameron AD, Stoebel DM, Dorman CJ. DNA supercoiling is differentially regulated by environmental factors and FIS in Escherichia coli and Salmonella enterica. Mol Microbiol 2011; 80(1):85-101.
221. Reyes-Dominguez Y, Contreras-Ferrat G, Ramirez-Santos J, Membrillo-Hernandez J, Gomez-Eichelmann MC. Plasmid DNA supercoiling and gyrase activity in Escherichia coli wild-type and rpoS stationary-phase cells. J Bacteriol 2003; 185(3):1097-100.
222. Weigl D, Molloy MJ, Clayton TM, et al. Characterization of a topologically aberrant plasmid population from pilot-scale production of clinical-grade DNA. J Biotechnol 2006; 121(1):1-12.
223. Benham CJ. Duplex destabilization in superhelical DNA is predicted to occur at specific transcriptional regulatory regions. J Mol Biol 1996; 255(3):425-34.
224. Lim HM, Lewis DE, Lee HJ, Liu M, Adhya S. Effect of varying the supercoiling of DNA on transcription and its regulation. Biochemistry 2003; 42(36):10718-25.
225. Azzoni AR, Ribeiro SC, Monteiro GA, Prazeres DM. The impact of polyadenylation signals on plasmid nuclease-resistance and transgene expression. J Gene Med 2007; 9(5):392-402.
226. van der Heijden I, Beijnen JH, Nuijen B. Long term stability of lyophilized plasmid DNA pDERMATT. Int J Pharm 2013; 453(2):648-50.
227. Zeng Y, Ramsey JD, King R, et al. Identifying stabilizers of plasmid DNA for pharmaceutical use. J Pharm Sci 2011; 100(3):904-14.
228. Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability--A step closer from promising technology to application. J Control Release 2011; 151(3):246-55.
229. Lee MJ, Cho SS, Jang HS, et al. Optimal salt concentration of vehicle for plasmid DNA enhances gene transfer mediated by electroporation. Exp Mol Med 2002; 34(4):265-72.
230. Wang XD, Tang JG, Xie XL, et al. A comprehensive study of optimal conditions for naked plasmid DNA transfer into skeletal muscle by electroporation. J Gene Med 2005; 7(9):1235-45.
231. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008; 26(3):440-8.
232. Draghia-Akli R, Khan AS, Brown PA, et al. Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine 2008; 26(40):5230-7.
233. Cai Y, Rodriguez S, Rameswaran R, Draghia-Akli R, Juba RJ, Jr., Hebel H. Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage. Vaccine 2010; 28(8):2046-52.
234. Hartikka J, Sukhu L, Buchner C, et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001; 4(5):407-15.
235. Mann CJ, Anguela XM, Montane J, et al. Molecular signature of the immune and tissue response to non-coding plasmid DNA in skeletal muscle after electrotransfer. Gene Ther 2012; 19(12):1177-86.
236. Donate A, Heller R. Assessment of delivery parameters with the multi-electrode array for development of a DNA vaccine against Bacillus anthracis. Bioelectrochemistry 2013; 94C:1-6.